CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $159.43B, higher than 95% of all stocks globally
- Interpretations14 currently firing — 14
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
As of FY2022 (year ended December 31, 2022). Newer annual figures aren't yet on file.
Financials view
Market Capitalization
136.47BEUR159.43B · vs all stocks (USD)
Trailing P/E
22.93xvs Biotechnology peers
Revenue (TTM)
176.95BDKK206.73B · vs all stocks (USD)
52-Week Change
-17.82%vs all stocks
Market Capitalization
136.47BEUR159.43B · vs all stocks (USD)
Enterprise Value
149.60BEUR174.77B · vs all stocks (USD)
Trailing P/E
22.93xvs Biotechnology peers
PEG Ratio
0.3997xvs Biotechnology peers
Price to Sales (TTM)
0.7712xvs Biotechnology peers
Price to Book (MRQ)
1.94xvs Biotechnology peers
Enterprise to Revenue
0.8454xvs Biotechnology peers
Enterprise to EBITDA
1.82xvs Biotechnology peers
Gross Margin
83.46%vs Biotechnology peers
Operating Margin
39.24%vs Biotechnology peers
Return on Assets (TTM)
23.01%vs Biotechnology peers
Return on Equity (TTM)
66.51%vs Biotechnology peers
Revenue (TTM)
176.95BDKK206.73B · vs all stocks (USD)
Revenue per Share (TTM)
39.06DKKUpdated Aug 22, 2026Quarterly Revenue Growth
8.16%vs Biotechnology peers
Gross Profit (TTM)
148.51BDKK173.49B · vs all stocks (USD)
EBITDA (TTM)
97.36BDKK113.74B · vs all stocks (USD)
Net Income (TTM)
55.52BDKK64.87B · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
28.89%vs Biotechnology peers
Operating Cash Flow (TTM)
75.57BDKK88.29B · vs all stocks (USD)
Levered Free Cash Flow (TTM)
55.52BDKK64.87B · vs all stocks (USD)
Revenue
176.95BDKKFY2022 · Dec 31, 2022Cost of Goods Sold
28.45BDKKFY2022 · Dec 31, 2022Gross Profit
148.51BDKKFY2022 · Dec 31, 2022Operating Income
74.81BDKK11.69B · vs all stocks (USD)
Pre-tax Income
69.06BDKKFY2022 · Dec 31, 2022Income Tax Expense
13.54BDKKFY2022 · Dec 31, 2022Net Income
55.52BDKKFY2022 · Dec 31, 2022EBIT
69.44BDKKFY2022 · Dec 31, 2022EBITDA (Income Statement)
82.04BDKKFY2022 · Dec 31, 2022Research & Development
24.05BDKKFY2022 · Dec 31, 2022Selling, General & Administrative
50.68BDKKFY2022 · Dec 31, 2022Other Operating Expenses
-1.03BDKKFY2022 · Dec 31, 2022Non-operating Interest Income
239.00MDKKFY2022 · Dec 31, 2022Non-operating Interest Expense
378.00MDKKFY2022 · Dec 31, 2022EPS (Basic)
12.26DKKFY2022 · Dec 31, 2022EPS (Diluted)
12.22DKKFY2022 · Dec 31, 2022Basic Shares Outstanding
4.53BSharesFY2022 · Dec 31, 2022Diluted Shares Outstanding
4.53BSharesFY2022 · Dec 31, 2022Net Income from Continuing Operations
55.52BDKKFY2022 · Dec 31, 2022Operating Cash Flow
75.57BDKKFY2022 · Dec 31, 2022Free Cash Flow
63.43BDKKFY2022 · Dec 31, 2022Cash & Cash Equivalents (End of Period)
12.65BDKKFY2022 · Dec 31, 2022Starting Profit (CF Statement)
55.52BDKKFY2022 · Dec 31, 2022Depreciation & Amortization
7.36BDKKFY2022 · Dec 31, 2022Deferred Taxes (CF)
13.54BDKKFY2022 · Dec 31, 2022Stock-based Compensation
1.54BDKKFY2022 · Dec 31, 2022Other Non-cash Items
1.38BDKKFY2022 · Dec 31, 2022Change in Accounts Receivable (CF)
-10.88BDKKFY2022 · Dec 31, 2022Change in Accounts Payable (CF)
6.72BDKKFY2022 · Dec 31, 2022Change in Other Assets/Liabilities
399.00MDKKFY2022 · Dec 31, 2022Capital Expenditures
-12.15BDKKFY2022 · Dec 31, 2022Net Intangibles (CF)
-2.61BDKKFY2022 · Dec 31, 2022Net Acquisitions
-7.08BDKKFY2022 · Dec 31, 2022Purchase of Investments
-9.73BDKKFY2022 · Dec 31, 2022Sale of Investments
6.64BDKKFY2022 · Dec 31, 2022Net Investing Cash Flow
-22.31BDKKFY2022 · Dec 31, 2022Long-term Debt Issuance
11.21BDKKFY2022 · Dec 31, 2022Long-term Debt Payments
-13.62BDKKFY2022 · Dec 31, 2022Common Stock Repurchase
-24.09BDKKFY2022 · Dec 31, 2022Common Dividends Paid
-25.30BDKKFY2022 · Dec 31, 2022Net Financing Cash Flow
-51.80BDKKFY2022 · Dec 31, 2022Shares Outstanding
3.40BSharesUpdated Aug 22, 2026Total Cash (MRQ)
30.14BDKK35.22B · vs all stocks (USD)
Total Cash per Share (MRQ)
6.73DKKUpdated Aug 22, 2026Total Debt (MRQ)
26.54BDKK31.00B · vs all stocks (USD)
Current Ratio (MRQ)
0.8241xvs Biotechnology peers
Book Value per Share (MRQ)
20.77DKKUpdated Aug 22, 2026Total Assets
241.26BDKK37.70B · vs all stocks (USD)
Total Current Assets
108.19BDKKFY2022 · Dec 31, 2022Total Liabilities
157.77BDKKFY2022 · Dec 31, 2022Total Non-current Assets
133.06BDKKFY2022 · Dec 31, 2022Total Non-current Liabilities
36.83BDKKFY2022 · Dec 31, 2022Total Current Liabilities
120.94BDKKFY2022 · Dec 31, 2022Cash
12.65BDKKFY2022 · Dec 31, 2022Cash & Cash Equivalents
12.65BDKKFY2022 · Dec 31, 2022Other Short-term Investments
10.92BDKKFY2022 · Dec 31, 2022Accounts Receivable
50.56BDKKFY2022 · Dec 31, 2022Inventory
24.39BDKKFY2022 · Dec 31, 2022Accounts Payable
15.59BDKKFY2022 · Dec 31, 2022Short-term Debt
1.47BDKKFY2022 · Dec 31, 2022Other Current Liabilities
26.51BDKKFY2022 · Dec 31, 2022Long-term Debt
24.32BDKKFY2022 · Dec 31, 2022Other Non-current Liabilities
100.00MDKKFY2022 · Dec 31, 2022Common Stock (Book)
456.00MDKKFY2022 · Dec 31, 2022Retained Earnings
80.59BDKKFY2022 · Dec 31, 2022Total Shareholders' Equity
83.49BDKK13.05B · vs all stocks (USD)
Treasury Stock
6.00MDKKFY2022 · Dec 31, 202252-Week Low
30.23EURUpdated Aug 22, 202652-Week High
54.87EURUpdated Aug 22, 202652-Week Change
-17.82%vs all stocks
50-Day MA
0.00EURUpdated Aug 22, 2026200-Day MA
0.00EURUpdated Aug 22, 2026Avg 10-Day Volume
137.78KSharesUpdated Aug 22, 2026Avg 30-Day Volume
179.59KSharesUpdated Aug 22, 2026Diluted EPS (TTM)
12.22DKKUpdated Aug 22, 2026Other Income / Expense
-5.43BDKKFY2022 · Dec 31, 202214 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
How does this company use capital?
Three Asset-Base Ratios Elevated
It gets more sales from its assets than its industry does, and a lot of profit from them too.
Reads
Cash Backing With Revenue And Income Streaks
Revenue has risen in each of three years, profit in all three, and it holds more cash than debt.
Reads
Cash-Flow Ratios Elevated
More of its sales turn into cash than in its industry, and less of that cash is consumed by reinvestment than at most of its peers.
Reads
FCF Ratios Elevated
Its free cash flow is large next to assets and equity, and more of its operating cash reaches it than in its industry.
Reads
Three Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion Levels
Its gross margin and its cash margin are high for its industry, and its operating margin is high outright.
Reads
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
Industry-Benchmarked Return on Capital Elevated
It earns more on its assets and its equity than its industry, and gets more sales from those assets.
Reads
Three Margin Ratios Elevated Across Gross, Operating, And Net Levels
Its gross and net margins are high for its industry, and its operating margin is high outright.
Reads
Multi-Year FCF With Growth And Margin
Three years of positive free cash flow and rising revenue, four of rising equity, and much of its sales turns into cash.
Reads
Revenue Growing With Receivables Growing
Revenue has risen three years, and what customers owe has risen with it.
Reads
ROE, ROA, And Operating ROA Elevated
It earns more on its equity than its industry does, and on its assets too — not on borrowing alone.
Reads
Is this company growing?
Revenue Growth With Elevated Margin
Revenue up in each of five years, while its operating margin stays high.
Reads
Where is this company structurally exposed?
Receivables Heavy and Growing
Money owed by customers keeps growing, and is much of its current assets.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $159.43B, higher than 95% of all stocks globallySignificant
Market cap (USD): 159,433,674,880.193Global P95: 25,614,208,870.135
Revenue is $206.73B, higher than 95% of all stocks globallySignificant
Revenue (USD): 206,728,280,040Global P95: 14,667,937,174.886
Levered free cash flow is $64.87B, higher than 95% of all stocks globallySignificant
Levered free cash flow (USD): 64,867,636,500Global P95: 1,123,592,359.78
Companies that share the same coordination system — how they create, deliver, or capture value.
Gilead Sciences Inc.
Tier 1ProductionApproval-Gated PipelineRule
Abbott Laboratories
Tier 1ProductionApproval-Gated PipelineRuleFlow
Pfizer Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Amgen Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Bristol-Myers Squibb Company
Tier 1ProductionApproval-Gated PipelineRuleFlow
Vertex Pharmaceuticals Incorporated
Tier 1ProductionApproval-Gated PipelineRule
Stryker Corporation
Tier 1ProductionApproval-Gated PipelineRuleFlow
Medtronic plc
Tier 1ProductionApproval-Gated PipelineRule
GSK plc
Tier 1ProductionApproval-Gated PipelineRuleFlow
AstraZeneca PLC
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
Games Workshop Group PLC
13 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesCash Backing With Revenue And Income StreaksFCF Ratios ElevatedROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedRevenue Growing With Receivables GrowingRevenue Growth With Elevated MarginIndustry-Benchmarked Return on Capital ElevatedIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net LevelsThree Asset-Base Ratios ElevatedMulti-Year FCF With Growth And Margin
Tips Music Ltd.
13 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesCash Backing With Revenue And Income StreaksFCF Ratios ElevatedROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedRevenue Growing With Receivables GrowingRevenue Growth With Elevated MarginIndustry-Benchmarked Return on Capital ElevatedIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net LevelsThree Asset-Base Ratios ElevatedMulti-Year FCF With Growth And Margin
Catalyst Pharmaceuticals Inc.
13 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesCash Backing With Revenue And Income StreaksFCF Ratios ElevatedROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedRevenue Growing With Receivables GrowingRevenue Growth With Elevated MarginIndustry-Benchmarked Return on Capital ElevatedIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net LevelsThree Asset-Base Ratios ElevatedMulti-Year FCF With Growth And Margin